KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Short term Debt (2016 - 2025)

Historic Short term Debt for Travere Therapeutics (TVTX) over the last 13 years, with Q2 2025 value amounting to $68.8 million.

  • Travere Therapeutics' Short term Debt changed N/A to $68.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $68.8 million, marking a year-over-year change of. This contributed to the annual value of $68.7 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Travere Therapeutics reported Short term Debt of $68.8 million as of Q2 2025.
  • Travere Therapeutics' 5-year Short term Debt high stood at $68.8 million for Q2 2025, and its period low was $6.9 million during Q1 2023.
  • Over the past 5 years, Travere Therapeutics' median Short term Debt value was $7.4 million (recorded in 2021), while the average stood at $29.6 million.
  • As far as peak fluctuations go, Travere Therapeutics' Short term Debt crashed by 5747.13% in 2021, and later plummeted by 540.54% in 2022.
  • Travere Therapeutics' Short term Debt (Quarter) stood at $7.4 million in 2021, then decreased by 5.41% to $7.0 million in 2022, then decreased by 1.43% to $6.9 million in 2023, then surged by 895.33% to $68.7 million in 2024, then increased by 0.23% to $68.8 million in 2025.
  • Its Short term Debt was $68.8 million in Q2 2025, compared to $68.8 million in Q1 2025 and $68.7 million in Q4 2024.